Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6NAJ

Integrin AlphaVBeta3 ectodomain bound to Hr10 variant of the 10th domain of Fibronectin.

Summary for 6NAJ
Entry DOI10.2210/pdb6naj/pdb
Related3IJE 4MMZ
DescriptorIntegrin alpha-V, Integrin beta-3, Fibronectin, HR10 variant, ... (9 entities in total)
Functional Keywordshybrid domain, psi, egf repeats, beta tail, calf, thigh, beta propeller, rgd motif, fibronectin, vitronectin, cell adhesion
Biological sourceHomo sapiens (human)
More
Total number of polymer chains3
Total formula weight197249.80
Authors
van Agthoven, J.,Arnaout, M.A. (deposition date: 2018-12-05, release date: 2019-12-11, Last modification date: 2023-11-15)
Primary citationAdair, B.D.,Alonso, J.L.,van Agthoven, J.,Hayes, V.,Ahn, H.S.,Yu, I.S.,Lin, S.W.,Xiong, J.P.,Poncz, M.,Arnaout, M.A.
Structure-guided design of pure orthosteric inhibitors of alpha IIb beta 3 that prevent thrombosis but preserve hemostasis.
Nat Commun, 11:398-398, 2020
Cited by
PubMed Abstract: A prevailing dogma is that inhibition of vascular thrombosis by antagonizing platelet integrin αIIbβ3 cannot be achieved without compromising hemostasis, thus causing serious bleeding and increased morbidity and mortality. It is speculated that these adverse outcomes result from drug-induced activating conformational changes in αIIbβ3 but direct proof is lacking. Here, we report the structure-guided design of peptide Hr10 and a modified form of the partial agonist drug tirofiban that act as "pure" antagonists of αIIbβ3, i.e., they no longer induce the conformational changes in αIIbβ3. Both agents inhibit human platelet aggregation but preserve clot retraction. Hr10 and modified tirofiban are as effective as partial agonist drugs in inhibiting vascular thrombosis in humanized mice, but neither causes serious bleeding, establishing a causal link between partial agonism and impaired hemostasis. Pure orthosteric inhibitors of αIIbβ3 may thus provide safer alternatives for human therapy, and valuable tools to probe structure-activity relationships in integrins.
PubMed: 31964886
DOI: 10.1038/s41467-019-13928-2
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.1 Å)
Structure validation

227111

PDB entries from 2024-11-06

PDB statisticsPDBj update infoContact PDBjnumon